New Alzheimer's Drugs Critically Evaluated: Limited Cognitive Benefits Despite Amyloid Reduction

A recent Cochrane network analysis has concluded that new Alzheimer's medications targeting amyloid plaques do not produce significant cognitive improvements in patients. The comprehensive review, which examined 17 clinical studies involving over 20,000 participants, focused on drugs including Lecanemab and Donanemab, which have been approved in the EU and show some capacity to slow cognitive decline.

Lead author Francesco Nonino from the IRCC Institute of Neurological Sciences in Bologna, Italy, stated, "Unfortunately, the evidence indicates that these drugs do not provide any meaningful difference for patients." The analysis assessed nine substances in total and found while these drugs effectively reduce amyloid plaques in the brain, the corresponding cognitive benefits remain minor.

Senior physician and professor Hugo Lövheim from Umeå University criticized the Cochrane study for grouping together both effective and ineffective substances, thereby diluting the overall results. He acknowledged that Lecanemab and Donanemab have shown some ability to slow cognitive decline, particularly if administered early in Alzheimer's progression, but emphasized these effects are modest.

Currently, Lecanemab is not yet available in Sweden, pending regulatory approval by the NT council, while Donanemab is in earlier stages of the approval process. Lövheim expressed hope that ongoing research will help identify specific patient groups who might benefit most from these treatments.

This critical evaluation highlights the ongoing debate over the clinical value of amyloid-targeting therapies amid their limited cognitive benefits despite reducing hallmark brain plaques associated with Alzheimer's disease.